Short answer
TANDEM DIABETES CARE INC (TNDM) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 8.01 (Other Events). FDA 510(k) clearance received November 12, 2026 for Tandem Mobi tubeless automated insulin delivery system.
TANDEM DIABETES CARE INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA 510(k) clearance received November 12, 2026 for Tandem Mobi tubeless automated insulin delivery system
- Tubeless infusion set cleared for up to 7 days, while cartridge remains cleared for 3 days
- Tandem Mobi now supports both tubeless and tubed configurations, expanding user choice versus competing pumps
- U.S. commercial launch planned for first half of 2027, creating a future product and revenue catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TANDEM DIABETES CARE INC 8-K filings
Get the next TNDM 8-K as it lands
Follow TNDM for push alerts, or ask the research agent what this filing means.